A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

This study is testing a combination of a targeted drug (BL-M07D1, an antibody-drug conjugate that targets the HER2 protein) plus an immunotherapy drug (pembrolizumab) in people with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that overexpresses the HER2 protein. **You may be eligible if...** - You are between 18 and 75 years old - You have locally advanced or metastatic non-squamous NSCLC - Your tumor has been confirmed to overexpress the HER2 protein - You have at least one measurable tumor on imaging - You are in good enough health to carry out daily activities - Your heart function is normal (ejection fraction ≥50%) **You may NOT be eligible if...** - You have received HER2-targeted therapy or antibody-drug conjugates using similar components before - Your cancer has spread to the brain or spinal fluid - You have had a serious heart attack, stroke, or significant heart problem in the past 6 months - You have active autoimmune disease, interstitial lung disease, or active hepatitis B, C, or HIV - You are pregnant or breastfeeding - You have had surgery, radiation, or immunotherapy within 4 weeks before the study Talk to your doctor to see if this trial is right for you.